| Identification | Back Directory | [Name]
(+)-ALPHA-DIHYDROTETRABENAZINE | [CAS]
3466-75-9 | [Synonyms]
DTBZ
DIHYDROTETRABENAZINE
(+)-ALPHA-DIHYDROTETRABEZINE
(+)-ALPHA-DIHYDROTETRABENAZINE
2H-Benzo[a]quinolizin-2-ol, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-
2H-BENZO[A]QUINOLIZINE-2-OL, 1,3,4,6,7,11B-HEXAHYDRO-3-ISOBUTYL-9,10-DIMETHOXY-
1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol | [Molecular Formula]
C19H29NO3 | [MDL Number]
MFCD08061467 | [MOL File]
3466-75-9.mol | [Molecular Weight]
319.44 |
| Chemical Properties | Back Directory | [Appearance]
Colourless solid | [Boiling point ]
457.8±45.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Chloroform: soluble; Methanol: soluble | [form ]
A solid | [pka]
14.75±0.40(Predicted) | [CAS DataBase Reference]
3466-75-9 |
| Hazard Information | Back Directory | [Chemical Properties]
Colourless solid | [Description]
Dihydrotetrabenazine is an active metabolite of the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine that is generated by hepatic carbonyl reductases. Dihydrotetrabenazine binds to mouse pons medulla, hypothalamus, and striatum (Kds = 2.72, 2.28, and 2.4 nM, respectively) and inhibits synaptic vesicular serotonin (5-HT) uptake (IC50s = 2.2, 2.8, and 2.3 nM, respectively). It also binds to human caudate nucleus, hippocampus, and substantia nigra pars compacta (Kds = 2.9, 2.5, and 2.8 nM, respectively). Dihydrotetrabenazine stereoisomers bind to VMAT2 in rat striatum. | [Uses]
Dihydrotetrabenazine (DHTBZ) is the active metabolite of Tetrabenazine (HY-B0590). Dihydrotetrabenazine is the inhibitor for human vesicular monoamine transporter 2 (VMAT2), that reduces monoamine content in presynaptic neurons, and can be used in movement disorder research[1]. | [Definition]
ChEBI: B-Dihydrotetrabenazine is a member of isoquinolines. | [storage]
Store at -20°C | [References]
[1] Chen JJ, et al., Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012 Jul;34(7):1487-504. DOI:10.1016/j.clinthera.2012.06.010 |
|
| Company Name: |
LOBERAN PHARMA
|
| Tel: |
+91-8368351617 +91-8006595568 |
| Website: |
www.loberanpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|